USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: ONCONOVA THERAPEUTICS, INC.
City: NEWTOWN
State: PA
Zip+4: 18940-3423
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,205,486.00 7
SBIR Phase II $845,883.00 1
STTR Phase I $203,744.00 1

Award List:

Pre-clinical Developmemt of a Novel COX-2 Inhibitor

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Stanley C. Bell
Award Amount: $100,000.00
Abstract:
DESCRIPTION (provided by applicant): Up-regulation of COX-2 has been reported to occur in cancer cells and selective inhibition of COX-2 has been demonstrated to reduce cancer cell growth in animal models. In addition, there has been a voluminous literature that suggests that cyclooxygenase-2… More

Use of Novel Cox-2 Inhibitors in Neurological Disorders

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Stanley C. Bell
Award Amount: $100,000.00
Abstract:
DESCRIPTION (provided by applicant): Up-regulation of COX-2 has also been reported to occur in human brains following a lethal cerebral ischemic insult and selective inhibition of COX-2 has been demonstrated to be neuroprotective in animal models. In addition, there has been a voluminous literature… More

Use of Novel Cox-2 Inhibitors in Neurological Disorders

Award Year / Program / Phase: 2005 / SBIR / Phase II
Agency: HHS
Principal Investigator: Stanley C. Bell
Award Amount: $845,883.00
Abstract:
DESCRIPTION (provided by applicant): Strategies aimed at limiting and repairing the damage attributed to oxidative stress may slow the advance of numerous age-related diseases. Numerous studies indicate that the enzyme cyclooxygenase-2 (COX-2) is induced by oxidative stress, contributes to oxidative… More

Novel Cyclooxygenase-2 Inhibitors: Epileptogenesis

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency: HHS
Principal Investigator: Stanley C. Bell
Award Amount: $218,796.00
Abstract:
DESCRIPTION (provided by applicant): Nearly 3% of the population in the United States has been diagnosed with some form of epilepsy at an estimated annual cost of >$12 billion. A major goal of translational research in the field of epilepsy is to develop therapies that prevent epilepsy development… More

Novel Therapeutic Strategy for Gliomas

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency: HHS
Principal Investigator: Stanley C. Bell
Award Amount: $135,546.00
Abstract:
DESCRIPTION (PROVIDED BY APPLICANT): Malignant gliomas are characterized by their ability to swiftly and diffusely invade from their primary foci into the surrounding normal brain parenchyma, making them surgically incurable. The failure to control invasive subpopulations of cells may be the key… More

Identification of Small Pharmacologic Inhibitors of HIV-1 Replication

Award Year / Program / Phase: 2007 / STTR / Phase I
Agency: HHS
Research Institution: TEMPLE UNIVERSITY
Principal Investigator: Xavier Grana
Award Amount: $203,744.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): HIV is the causative agent of AIDS (Acquired Immunodeficiency Syndrome). In 2005 the estimated number of individuals living with AIDS worldwide was about 40.3 million. While the rate of HIV infection has started to decr ease in several countries, the total number… More

Evaluation of novel cytotoxic compounds for immunoconjugates

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: Stanley C. Bell
Award Amount: $155,103.00
Abstract:
DESCRIPTION (provided by applicant): The remarkable commercial and medical success of monoclonal antibodies has led to the exploration of variations of this therapeutic modality. One approach, which is particularly suited for anticancer therapy, involves A ntibody-Drug Conjugates (ADCs), or… More

Development of a Small Molecule-Targeted Therapy for Mantle Cell Lymphoma

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $220,180.00
Abstract:
DESCRIPTION (provided by applicant): Mantle cell lymphoma (MCL) is an aggressive subtype of non-Hodgkin's lymphoma (NHL) that accounts for 5- 8% of all lymphoma cases. The disease is typically found in older adults with a higher incidence in males that pre sent with advanced disease. MCL has one of… More

Development of a Selective PLK2 Inhibitor for Cancer Therapy

Award Year / Program / Phase: 2011 / SBIR / Phase I
Agency: HHS
Principal Investigator: Manoj Maniar – 267-759-3680
Award Amount: $275,861.00
Abstract:
DESCRIPTION (provided by applicant): The recent success of imatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukemia has made tyrosine and serine/threonine kinases as major targets for cancer therapy. Currently, since only a small fraction of the human kinome has… More